ArticleDiscover nano2026
Engineering L-Arg@ZIF-8 nanoparticles to modulate the immune-osteogenic-angiogenic microenvironment for accelerated bone fracture healing.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bone fracture healing requires coordinated regulation of osteogenesis, angiogenesis, and immune homeostasis within a dynamically evolving microenvironment. However, current biomaterials rarely integrate these three regulatory dimensions. Herein, we engineered L-arginine-loaded zeolitic imidazolate framework-8 (L-Arg@ZIF-8) nanoparticles to remodel the immune-osteogenic-angiogenic microenvironment and accelerate fracture healing. L-Arg@ZIF-8 nanoparticles exhibited uniform morphology, positive surface charge, and stable L-Arg incorporation, enabling efficient cellular uptake and sustained bioactivity. Using two physiologically relevant 3D co-culture spheroid models (osteoblast-macrophage and osteoblast-endothelial), we demonstrated that L-Arg@ZIF-8 promotes osteogenic differentiation, endothelial activation and the upregulation of angiogenic markers, and strengthens osteogenesis-angiogenesis coupling. Bulk transcriptomic profiling further revealed activation of regenerative pathways, including PI3K-Akt and Wnt signaling, along with coordinated modulation of cytokine-receptor interactions and immune-related remodeling programs. In vivo, L-Arg@ZIF-8 markedly accelerated fracture repair in a rat rib fracture model, characterized by enhanced callus formation, increased bone mineral density, greater trabecular thickness, and a significantly elevated mineral apposition rate. Histological and immunofluorescence analyses confirmed upregulation of key osteogenic markers (OPN, OSX) at the fracture site. Together, these findings demonstrate that L-Arg@ZIF-8 functions as a bioengineered microenvironment-modulating nanoplatform that orchestrates immune regulation, osteogenesis, and angiogenesis to promote efficient fracture healing. This strategy offers a promising therapeutic avenue for translational management of complex fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.